A single long-term follow up assessment of an established multi-centre, prospective longitudinal cohort study of patients for clinical, psychosocial, immunovirological outcomes 4 to 8 years after previous treatment for recently acquired hepatitis C virus infection.
The study aims are: 1. To evaluate the effect of successful prior treatment or spontaneous clearance of recently acquired HCV infection on long-term quality of life, social functioning, injecting behaviour, mental health and liver health. 2. To assess the incidence of HCV re-infection following prior treatment induced clearance or spontaneous clearance of recently acquired chronic HCV infection. 3. To determine predictors of HCV re-infection following recently acquired HCV infection treatment. 4. To determine frequency and predictors of new mixed and superinfections in ATAHC subjects with persistent viraemia. 5. To add to a tissue repository of serum and PBMCs from well-characterised patients treated for recently acquired HCV infection to allow future examination of the role of other variables that may potentially impact on the prognosis and outcomes of early HCV treatment.
Study Type
OBSERVATIONAL
Enrollment
50
St Vincent's Hospital
Sydney, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Long-term effects of HCV clearance
Health related quality of life (measured by SF-12) Social functioning (measured by OTI survey) Injecting behaviour Mental health (measured by DASS and MINI) Liver health (measured by FibroScan and biochemical markers)
Time frame: 4 to 8 years from initial infection
Incidence of HCV re-infection
Rate of HCV RNA positivity in patients previously HCV RNA negative.
Time frame: 4 to 8 years from initial infection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.